Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
PVLA
PVLA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PVLA News
Palvella Launches Awareness Campaign for Microcystic Lymphatic Malformations
2h ago
Newsfilter
Palvella Closes $230 Million Upsized Public Offering
Mar 02 2026
Newsfilter
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
Palvella Therapeutics Prices $200 Million Upsized Public Offering
Feb 26 2026
NASDAQ.COM
Palvella Therapeutics Successfully Prices Upsized Public Offering
Feb 26 2026
Yahoo Finance
Wall Street Analysts Adjust Ratings
Feb 25 2026
Benzinga
US Stocks Rebound Led by Software and Chipmakers
Feb 25 2026
NASDAQ.COM
US Stocks Rebound Led by Software and Chipmakers
Feb 24 2026
NASDAQ.COM
U.S. Stocks Rise with Dow Jones Up Over 400 Points
Feb 24 2026
Benzinga
Palvella Therapeutics Shares Surge 30% After Successful Trial Results
Feb 24 2026
seekingalpha
US Stocks Rebound Slightly as Software Shares Recover
Feb 24 2026
NASDAQ.COM
Palvella Therapeutics SELVA Trial Success Boosts Stock
Feb 24 2026
Benzinga
U.S. Stocks Mixed in Morning Trade; Dow Jones Up Over 100 Points
Feb 24 2026
Benzinga
Palvella's QTORIN Gel Shows Positive Phase 3 Results for Rare Lymphatic Condition
Feb 24 2026
NASDAQ.COM
Palvella Therapeutics Shares Surge 45% on Positive Phase 3 Study Results
Feb 24 2026
stocktwits
Palvella's QTORIN™ Rapamycin Shows Significant Phase 3 Trial Results for Microcystic Lymphatic Malformations
Feb 24 2026
Newsfilter
Show More News
